BIOLIGHT LIFE (Israel) Financial Diagnostics

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 15px;;'>BI</div>
The current investor indifference towards the small price fluctuations of BIOLIGHT LIFE SCI could raise concerns from investors as the firm closed today at a share price of 0.0 on very low momentum in volume. The company management did not add any value to BIOLIGHT LIFE investors in December. However, most investors can still diversify their portfolios with BIOLIGHT LIFE SCI to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. This diagnostics interface makes it easy to digest most current publicly released information about BIOLIGHT LIFE as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis BIOLIGHT LIFE price relationship with some important fundamental indicators such as market cap and management efficiency. Continue to Trending Equities.


The company recorded earning per share (EPS) of 14.32. BIOLIGHT LIFE SCI had not issued any dividends in recent years. The entity had 1:10 split on 2016-02-28. BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel. BIOLIGHT LIFE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. For more info on BIO LIGHT ISR LFE please contact Suzana NahumZilberberg at 972 7 327 53400 or go to


BIOLIGHT LIFE SCI is not yet fully synchronised with the market data
BIOLIGHT LIFE SCI has some characteristics of a very speculative penny stock
BIOLIGHT LIFE SCI has high likelihood to experience some financial distress in the next 2 years
BIO LIGHT ISR LFE has accumulated about 39.85 M in cash with (22.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.77.

Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.29 B.

Management Efficiency

BIOLIGHT LIFE SCI has return on total asset (ROA) of (21.32) % which means that it has lost $21.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 103.73 % meaning that it generated $103.73 on every $100 dollars invested by stockholders.

BIOLIGHT LIFE Technical and Predictive Indicators

Did you try this?

Run Portfolio Diagnostics Now


Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module
Continue to Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Company logos by clearbit